Answers are grounded in this paper and cite their sources.
Chronic graft-versus-host disease (cGVHD) contributes substantially to morbidity and mortality in allogeneic hematopoietic stem cell transplant recipients. Microbe-derived short-chain fatty acids (SCFA) exert diverse local effects on the intestinal mucosa. We previously reported that a relative deficiency of SCFA in the circulation of transplant patients was associated with an increased incidence of cGVHD. We therefore hypothesized that circulating SCFA were unrecognized immunomodulators, generating protective effects after transplantation. We examined the role of SCFA butyrate and propionate in mouse models of cGVHD and now report that systemic administration of either butyrate or propionate mitigates cGVHD and improves survival. Exogenous SCFA treatment reduced pathogenic hyperexpanded B cells and recipient-specific IgA in the circulation, as well as decreasing the total alloantibody pool, defined using rapid extracellular antigen profiling (REAP). Our findings uncover a mechanism by which the intestinal microbiome plays a role in regulating antibody-dependent cGVHD pathogenesis and has implications for other antibody-mediated pathologies.
No takes yet. Share an insight, caveat, or question.
Wolfe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: